Home » VIOQUEST PHARMACEUTICAL'S TARGETED CANCER THERAPEUTIC FOR SOLID TUMORS BEGINS TRIALS AT MOFFITT CANCER CENTER
VIOQUEST PHARMACEUTICAL'S TARGETED CANCER THERAPEUTIC FOR SOLID TUMORS BEGINS TRIALS AT MOFFITT CANCER CENTER
VioQuest Pharmaceuticals, a New Jersey-based biopharmaceutical company focused on acquiring, developing and commercializing
targeted cancer compounds, has initiated a Phase I/IIa clinical trial to assess the safety and dosing of VQD-002, triciribine-phosphate (TCN-P).
PR Leap
KEYWORDS FDAnews Drug Daily Bulletin
Upcoming Events
-
23Apr
-
25Apr
-
07May
-
14May
-
30May